{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:09:21Z","timestamp":1788804561803,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82301270"],"award-info":[{"award-number":["No. 82301270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82171016"],"award-info":[{"award-number":["No. 82171016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Basic Research Program of Wenzhou Medical University","award":["KYYW202302"],"award-info":[{"award-number":["KYYW202302"]}]},{"name":"National Key Research and Development Program of China","award":["No. 2023YFC3605400"],"award-info":[{"award-number":["No. 2023YFC3605400"]}]},{"name":"Chongqing Science and Health Joint Fund","award":["No. 2024GGXM003"],"award-info":[{"award-number":["No. 2024GGXM003"]}]},{"name":"\"Pioneer\" and \"Leading Goose\" R&D Program of Zhejiang","award":["2026C02A1152"],"award-info":[{"award-number":["2026C02A1152"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02111-7","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:47:08Z","timestamp":1782222428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outer nuclear layer thinning as an in vivo biomarker for discriminating probable FTLD-tau from probable FTLD-TDP with PET-supported subtyping"],"prefix":"10.1186","volume":"18","author":[{"given":"Zhengxi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijie","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meizhen","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Jiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixiao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"1","key":"2111_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","volume":"119","author":"IRA Mackenzie","year":"2009","unstructured":"Mackenzie IRA, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2009;119(1):1\u20134. https:\/\/doi.org\/10.1007\/s00401-009-0612-2.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2111_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00401-014-1380-1","volume":"129","author":"DJ Irwin","year":"2014","unstructured":"Irwin DJ, Cairns NJ, Grossman M, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2014;129(4):469\u201391. https:\/\/doi.org\/10.1007\/s00401-014-1380-1.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2111_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","volume":"20","author":"GU H\u00f6glinger","year":"2021","unstructured":"H\u00f6glinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(3):182\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(20)30489-0.","journal-title":"Lancet Neurol"},{"issue":"6","key":"2111_CR4","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery CJ, B\u00f6rjesson-Hanson A, Blackburn DJ, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023;29(6):1437\u201347. https:\/\/doi.org\/10.1038\/s41591-023-02326-3.","journal-title":"Nat Med"},{"issue":"4","key":"2111_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s13311-022-01260-5","volume":"19","author":"LR Hayes","year":"2022","unstructured":"Hayes LR, Kalab P. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS\/FTD. Neurotherapeutics. 2022;19(4):1061\u201384. https:\/\/doi.org\/10.1007\/s13311-022-01260-5.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"2111_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/jnnp-2021-327497","volume":"93","author":"D Irwin","year":"2021","unstructured":"Irwin D. Preparing for the age of therapeutic trials in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2021;93(2):115. https:\/\/doi.org\/10.1136\/jnnp-2021-327497.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"2111_CR7","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.2967\/jnumed.121.262854","volume":"63","author":"K Messerschmidt","year":"2022","unstructured":"Messerschmidt K, Barthel H, Brendel M, et al. 18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy. J Nucl Med. 2022;63(11):1754\u201360. https:\/\/doi.org\/10.2967\/jnumed.121.262854.","journal-title":"J Nucl Med"},{"issue":"1","key":"2111_CR8","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, et al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025;21(1):e14338. https:\/\/doi.org\/10.1002\/alz.14338.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2111_CR9","doi-asserted-by":"publisher","first-page":"9357","DOI":"10.1038\/s41467-025-64541-5","volume":"16","author":"DJ Irwin","year":"2025","unstructured":"Irwin DJ. The potential of TDP-43 PET ligands for a biological diagnosis of TDP-43 proteinopathies. Nat Commun. 2025;16(1):9357. https:\/\/doi.org\/10.1038\/s41467-025-64541-5.","journal-title":"Nat Commun"},{"issue":"10","key":"2111_CR10","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/jnnp-2024-335723","volume":"96","author":"AT Zhao","year":"2025","unstructured":"Zhao AT, Nair RM, Lee EB, et al. Retinal imaging and tissue analysis for frontotemporal degeneration: recent advances and challenges for biomarker development. J Neurol Neurosurg Psychiatry. 2025;96(10):1012\u201322. https:\/\/doi.org\/10.1136\/jnnp-2024-335723.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"2111_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3233\/JAD-160886","volume":"56","author":"L Ferrari","year":"2017","unstructured":"Ferrari L, Huang S-C, Magnani G, et al. Optical Coherence Tomography Reveals Retinal Neuroaxonal Thinning in Frontotemporal Dementia as in Alzheimer\u2019s Disease. J Alzheimer\u2019s Disease: JAD. 2017;56(3):1101\u20137. https:\/\/doi.org\/10.3233\/JAD-160886.","journal-title":"J Alzheimer\u2019s Disease: JAD"},{"issue":"1","key":"2111_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-021-00230-9","volume":"10","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang Y, Shi C, et al. Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer\u2019s disease. Transl Neurodegener. 2021;10(1):6. https:\/\/doi.org\/10.1186\/s40035-021-00230-9.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"2111_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13195-025-01676-z","volume":"17","author":"Z Jin","year":"2025","unstructured":"Jin Z, Wang X, Lang Y, et al. Retinal optical coherence tomography intensity spatial correlation features as new biomarkers for confirmed Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17(1):33. https:\/\/doi.org\/10.1186\/s13195-025-01676-z.","journal-title":"Alzheimers Res Ther"},{"issue":"15","key":"2111_CR14","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1212\/WNL.0000000000004500","volume":"89","author":"BJ Kim","year":"2017","unstructured":"Kim BJ, Irwin DJ, Song D, et al. Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. Neurology. 2017;89(15):1604\u201311. https:\/\/doi.org\/10.1212\/WNL.0000000000004500.","journal-title":"Neurology"},{"key":"2111_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neurobiolaging.2023.01.015","volume":"125","author":"BJ Kim","year":"2023","unstructured":"Kim BJ, Grossman M, Aleman TS, et al. Retinal photoreceptor layer thickness has disease specificity and distinguishes predicted FTLD-Tau from biomarker-determined Alzheimer\u2019s disease. Neurobiol Aging. 2023;125:74\u201382. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2023.01.015.","journal-title":"Neurobiol Aging"},{"key":"2111_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fnins.2019.00298","volume":"13","author":"BJ Kim","year":"2019","unstructured":"Kim BJ, Grossman M, Song D, et al. Persistent and Progressive Outer Retina Thinning in Frontotemporal Degeneration. Front Neurosci. 2019;13:298. https:\/\/doi.org\/10.3389\/fnins.2019.00298.","journal-title":"Front Neurosci"},{"issue":"1","key":"2111_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40478-021-01290-8","volume":"9","author":"BJ Kim","year":"2021","unstructured":"Kim BJ, Lee V, Lee EB, et al. Retina tissue validation of optical coherence tomography determined outer nuclear layer loss in FTLD-tau. Acta Neuropathol Commun. 2021;9(1):184. https:\/\/doi.org\/10.1186\/s40478-021-01290-8.","journal-title":"Acta Neuropathol Commun"},{"key":"2111_CR18","doi-asserted-by":"publisher","first-page":"964715","DOI":"10.3389\/fnins.2022.964715","volume":"16","author":"BM Wong","year":"2022","unstructured":"Wong BM, Hudson C, Snook E, et al. Retinal nerve fiber layer in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Front Neurosci. 2022;16:964715. https:\/\/doi.org\/10.3389\/fnins.2022.964715.","journal-title":"Front Neurosci"},{"issue":"10","key":"2111_CR19","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1084\/jem.20140214","volume":"211","author":"ME Ward","year":"2014","unstructured":"Ward ME, Taubes A, Chen R, et al. Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J Exp Med. 2014;211(10):1937\u201345. https:\/\/doi.org\/10.1084\/jem.20140214.","journal-title":"J Exp Med"},{"issue":"5","key":"2111_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00401-023-02623-8","volume":"146","author":"AA Dijkstra","year":"2023","unstructured":"Dijkstra AA, Morrema THJ, Hart de Ruyter FJ, et al. TDP-43 pathology in the retina of patients with frontotemporal lobar degeneration. Acta Neuropathol. 2023;146(5):767\u201370. https:\/\/doi.org\/10.1007\/s00401-023-02623-8.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2111_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00401-024-02769-z","volume":"148","author":"FJ Hart de Ruyter","year":"2024","unstructured":"Hart de Ruyter FJ, Evers MJAP, Morrema THJ, et al. Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases. Acta Neuropathol. 2024;148(1):24. https:\/\/doi.org\/10.1007\/s00401-024-02769-z.","journal-title":"Acta Neuropathol"},{"key":"2111_CR22","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.29.595206","author":"LX Tan","year":"2024","unstructured":"Tan LX, Oertel FC, Cheng A, et al. Targeting complement C3a receptor resolves mitochondrial hyperfusion and subretinal microglial activation in progranulin-deficient frontotemporal dementia. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.05.29.595206.","journal-title":"bioRxiv"},{"issue":"4","key":"2111_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/0891988711422528","volume":"24","author":"J Lu","year":"2011","unstructured":"Lu J, Li D, Li F, et al. Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study. J Geriatr Psychiatry Neurol. 2011;24(4):184\u201390. https:\/\/doi.org\/10.1177\/0891988711422528.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"5","key":"2111_CR24","doi-asserted-by":"publisher","first-page":"e213401","DOI":"10.1212\/wnl.0000000000213401","volume":"104","author":"L de Boer","year":"2025","unstructured":"de Boer L, Poos JM, Van Den Berg E, et al. Montreal Cognitive Assessment vs the Mini-Mental State Examination as a Screening Tool for Patients With Genetic Frontotemporal Dementia. Neurology. 2025;104(5):e213401. https:\/\/doi.org\/10.1212\/wnl.0000000000213401.","journal-title":"Neurology"},{"issue":"12","key":"2111_CR25","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/s1474-4422(19)30354-0","volume":"18","author":"EL van der Ende","year":"2019","unstructured":"van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019;18(12):1103\u201311. https:\/\/doi.org\/10.1016\/s1474-4422(19)30354-0.","journal-title":"Lancet Neurol"},{"issue":"3","key":"2111_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","volume":"76","author":"B Olsson","year":"2019","unstructured":"Olsson B, Portelius E, Cullen NC, et al. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurol. 2019;76(3):318\u201325. https:\/\/doi.org\/10.1001\/jamaneurol.2018.3746.","journal-title":"JAMA Neurol"},{"issue":"Pt 9","key":"2111_CR27","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456\u201377. https:\/\/doi.org\/10.1093\/brain\/awr179.","journal-title":"Brain"},{"issue":"11","key":"2111_CR28","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006\u201314. https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6.","journal-title":"Neurology"},{"issue":"6","key":"2111_CR29","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364. https:\/\/doi.org\/10.1002\/mds.26987.","journal-title":"Mov Disord"},{"issue":"2","key":"2111_CR30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-021-05603-w","volume":"49","author":"E Guedj","year":"2022","unstructured":"Guedj E, Varrone A, Boellaard R, et al. EANM procedure guidelines for brain PET imaging using [(18)F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49(2):632\u201351. https:\/\/doi.org\/10.1007\/s00259-021-05603-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2111_CR31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/ene.13728","volume":"25","author":"F Nobili","year":"2018","unstructured":"Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain (18) F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25(10):1201\u201317. https:\/\/doi.org\/10.1111\/ene.13728.","journal-title":"Eur J Neurol"},{"issue":"Suppl 2","key":"2111_CR32","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2967\/jnumed.124.268756","volume":"66","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, et al. Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. J Nucl Med. 2025;66(Suppl 2):S5\u201331. https:\/\/doi.org\/10.2967\/jnumed.124.268756.","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"2111_CR33","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.2967\/jnumed.124.268754","volume":"66","author":"J Arbizu","year":"2025","unstructured":"Arbizu J, Morbelli S, Minoshima S, et al. SNMMI Procedure Standard\/EANM Practice Guideline for Brain [(18)F]FDG PET Imaging, Version 2.0. J Nucl Med. 2025;66(Suppl 2):S45\u201360. https:\/\/doi.org\/10.2967\/jnumed.124.268754.","journal-title":"J Nucl Med"},{"issue":"1","key":"2111_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-007-0237-2","volume":"114","author":"NJ Cairns","year":"2007","unstructured":"Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114(1):5\u201322. https:\/\/doi.org\/10.1007\/s00401-007-0237-2.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2111_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1.","journal-title":"Neurology"},{"issue":"4","key":"2111_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s00415-014-7256-4","volume":"261","author":"N Zalewski","year":"2014","unstructured":"Zalewski N, Botha H, Whitwell JL, et al. FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. J Neurol. 2014;261(4):710\u20136. https:\/\/doi.org\/10.1007\/s00415-014-7256-4.","journal-title":"J Neurol"},{"issue":"23","key":"2111_CR37","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1212\/WNL.0b013e31823b9c5e","volume":"77","author":"GD Rabinovici","year":"2011","unstructured":"Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77(23):2034\u201342. https:\/\/doi.org\/10.1212\/WNL.0b013e31823b9c5e.","journal-title":"Neurology"},{"issue":"6","key":"2111_CR38","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2967\/jnumed.123.265930","volume":"65","author":"GN Bischof","year":"2024","unstructured":"Bischof GN, Brendel M, Barthel H, et al. Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620. J Nucl Med. 2024;65(6):952\u20135. https:\/\/doi.org\/10.2967\/jnumed.123.265930.","journal-title":"J Nucl Med"},{"issue":"4","key":"2111_CR39","doi-asserted-by":"publisher","first-page":"e229588","DOI":"10.1001\/jamanetworkopen.2022.9588","volume":"5","author":"I Ill\u00e1n-Gala","year":"2022","unstructured":"Ill\u00e1n-Gala I, Nigro S, VandeVrede L, et al. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Netw Open. 2022;5(4):e229588. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.9588.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2111_CR40","doi-asserted-by":"publisher","first-page":"6896","DOI":"10.1002\/alz.14185","volume":"20","author":"R Dilcher","year":"2024","unstructured":"Dilcher R, Wall S, Gro\u00df M, et al. Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer\u2019s disease and 4R-tauopathies. Alzheimers Dement. 2024;20(10):6896\u2013909. https:\/\/doi.org\/10.1002\/alz.14185.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2111_CR41","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","volume":"77","author":"M Brendel","year":"2020","unstructured":"Brendel M, Barthel H, van Eimeren T, et al. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020;77(11):1408\u201319. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2526.","journal-title":"JAMA Neurol"},{"issue":"8","key":"2111_CR42","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","volume":"47","author":"S Morbelli","year":"2020","unstructured":"Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47(8):1885\u2013912. https:\/\/doi.org\/10.1007\/s00259-020-04817-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2111_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41572-023-00447-0","volume":"9","author":"M Grossman","year":"2023","unstructured":"Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. https:\/\/doi.org\/10.1038\/s41572-023-00447-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2111_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40035-024-00419-8","volume":"13","author":"JI L\u00f3pez-Carbonero","year":"2024","unstructured":"L\u00f3pez-Carbonero JI, Garc\u00eda-Toledo I, Fern\u00e1ndez-Hern\u00e1ndez L, et al. In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use. Transl Neurodegener. 2024;13(1):29. https:\/\/doi.org\/10.1186\/s40035-024-00419-8.","journal-title":"Transl Neurodegener"},{"key":"2111_CR45","doi-asserted-by":"publisher","unstructured":"Liu X, Shen M, Yuan Y, et al. Macular Thickness Profiles of Intraretinal Layers in Myopia Evaluated by Ultrahigh-Resolution Optical Coherence Tomography. Am J Ophthalmol. 2015;160(1). https:\/\/doi.org\/10.1016\/j.ajo.2015.03.012.","DOI":"10.1016\/j.ajo.2015.03.012"},{"issue":"8","key":"2111_CR46","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/s0895-4356(01)00341-9","volume":"54","author":"EW Steyerberg","year":"2001","unstructured":"Steyerberg EW, Harrell FE Jr., Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54(8):774\u201381. https:\/\/doi.org\/10.1016\/s0895-4356(01)00341-9.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2111_CR47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00401-022-02525-1","volume":"145","author":"FJ Hart de Ruyter","year":"2022","unstructured":"Hart de Ruyter FJ, Morrema THJ, den Haan J, et al. Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer\u2019s disease and primary tauopathies. Acta Neuropathol. 2022;145(2):197\u2013218. https:\/\/doi.org\/10.1007\/s00401-022-02525-1.","journal-title":"Acta Neuropathol"},{"key":"2111_CR48","doi-asserted-by":"publisher","unstructured":"Bujakowska KM, Liu Q, Pierce EA. Photoreceptor Cilia and Retinal Ciliopathies. Cold Spring Harb Perspect Biol. 2017;9(10). https:\/\/doi.org\/10.1101\/cshperspect.a028274.","DOI":"10.1101\/cshperspect.a028274"},{"issue":"6","key":"2111_CR49","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1074\/mcp.M800406-MCP200","volume":"8","author":"R Fridlich","year":"2009","unstructured":"Fridlich R, Delalande F, Jaillard C, et al. The thioredoxin-like protein rod-derived cone viability factor (RdCVFL) interacts with TAU and inhibits its phosphorylation in the retina. Mol Cell Proteom. 2009;8(6):1206\u201318. https:\/\/doi.org\/10.1074\/mcp.M800406-MCP200.","journal-title":"Mol Cell Proteom"},{"issue":"1","key":"2111_CR50","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-022-01489-3","volume":"11","author":"L Arouche-Delaperche","year":"2023","unstructured":"Arouche-Delaperche L, Cadoni S, Joffrois C, et al. Dysfunction of the glutamatergic photoreceptor synapse in the P301S mouse model of tauopathy. Acta Neuropathol Commun. 2023;11(1):5. https:\/\/doi.org\/10.1186\/s40478-022-01489-3.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"2111_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40478-021-01120-x","volume":"9","author":"JF Striebel","year":"2021","unstructured":"Striebel JF, Race B, Leung JM, et al. Prion-induced photoreceptor degeneration begins with misfolded prion protein accumulation in cones at two distinct sites: cilia and ribbon synapses. Acta Neuropathol Commun. 2021;9(1):17. https:\/\/doi.org\/10.1186\/s40478-021-01120-x.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"2111_CR52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s43657-022-00068-9","volume":"3","author":"M Tian","year":"2023","unstructured":"Tian M, Zuo C, Civelek AC, et al. International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer\u2019s Disease. Phenomics. 2023;3(4):375\u201389. https:\/\/doi.org\/10.1007\/s43657-022-00068-9.","journal-title":"Phenomics"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02111-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02111-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02111-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:02:58Z","timestamp":1788804178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02111-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2111"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02111-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committees of Wenzhou Medical University and the Army Medical Center of PLA (Approval Nos. 2020-012-K-10 and 2020-14) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants or their legal representatives.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors read and approved the final manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"199"}}